27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's disease (AD) is a currently incurable neurodegenerative disorder and is the most common form of dementia in people over the age of 65 years. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Progressive supranuclear palsy (PSP) is a movement disorder characterized by tau neuropathology where the underlying mechanism is unknown. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Key points High frequency (100-250 Hz) neuronal oscillations in the hippocampus, known as sharp-wave ripples (SWRs), synchronise the firing behaviour of groups of neurons and play a key role in memory consolidation. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
For several years Amyloid-beta peptide (Aβ) has been considered the main pathogenetic factor of Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Abnormal hyperphosphorylation of microtubule-associated protein tau is involved in the pathogenesis of several neurodegenerative disorders including Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Crocin, as a carotenoid, is one of the main and active constituents of saffron stigmas (Crocus sativus L.) that is widely used in folk medicine. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obesity and type 2 diabetes mellitus (T2DM) convey an increased risk for developing dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive training, physical activity, and exercise have often been reported to improve cognitive performance in older adults. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The unprecedented growth in the number of older adults in our society is accompanied by the exponential increase in the number of elderly people who will suffer cognitive decline and dementia in the next decades. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) share clinical and pathological similarities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The rise in the ageing population has resulted in increased incident rates of cognitive impairment and dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid diseases are characterized by the deposition of typically aggregated proteins/peptides in tissues, associated with degeneration and progressive functional impairment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The International Conference on Harmonization considers older people a 'special population', as they differ from younger adults in terms of comorbidity, polypharmacy, pharmacokinetics and greater vulnerability to adverse drug reactions (ADRs). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A large percentage of patients subjected to general anesthesia at 65 years and older exhibit postoperative delirium (POD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older adults who survive critical illness have physical and cognitive declines resulting in disability at greater rates than hospitalized, noncritically ill and community dwelling older adults. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
End-of-life transitions between health care settings are common across EU countries, in particular late hospitalizations for people residing at home. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
National dementia strategies cover part of the recent definition of palliative care in dementia, although they do not frequently label these references as "palliative care." 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The early integration of specialist palliative care has been shown to benefit the quality of life of patients with advanced cancer. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our results help to elucidate the tasks and roles required of FPs to make integration of a palliative care approach into the care continuum possible. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Physicians should consider advanced dementia as a terminal disease for which there is a continuum of care that goes from palliative care with life-extending measures to symptomatic interventions only. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Benefits of palliative care in dementia are acknowledged by experts worldwide, but there is some controversy around its early introduction. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Educating families and professionals about palliative care is important as many professionals and non-professionals believe that this approach intends to hasten death, instead of affirming life and regarding dying as a normal process. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The uptake of advance care planning (ACP) is particularly low among people with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Automated analysis of MRI data of the subregions of the hippocampus requires computational atlases built at a higher resolution than those that are typically used in current neuroimaging studies. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →